Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • oral therapy
Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Orforglipron: A Promising Oral Small-Molecule GLP-1 Receptor Agonist for Early Type 2 Diabetes and Obesity Management

Posted by MedXY By MedXY 09/17/2025
Orforglipron demonstrates significant glycemic control and weight reduction benefits in early type 2 diabetes and obesity, with favorable safety and oral administration convenience.
Read More
Oral Regimens for Whipple’s Disease: A Non-Inferiority Trial of Doxycycline-Hydroxychloroquine Versus Standard Intravenous Therapy
Posted inClinical Updates news Rheumatology Specialties

Oral Regimens for Whipple’s Disease: A Non-Inferiority Trial of Doxycycline-Hydroxychloroquine Versus Standard Intravenous Therapy

Posted by MedXY By MedXY 08/03/2025
A German phase 2/3 trial found oral doxycycline-hydroxychloroquine as effective and safe as standard intravenous ceftriaxone followed by oral trimethoprim-sulfamethoxazole for Whipple’s disease, potentially transforming outpatient management.
Read More
EMA Recommends First Oral On-Demand Therapy for Hereditary Angioedema: A Paradigm Shift in Acute Attack Management
Posted inClinical Updates news Pediatrics Specialties

EMA Recommends First Oral On-Demand Therapy for Hereditary Angioedema: A Paradigm Shift in Acute Attack Management

Posted by MedXY By MedXY 07/30/2025
EMA endorses sebetralstat, the first oral on-demand therapy for hereditary angioedema, following positive results from the KONFIDENT phase 3 trial, offering a more convenient and rapid treatment option for acute attacks.
Read More
  • Ultra-Early ILR Implantation Post-Cryptogenic Stroke Dramatically Improves Silent AF Detection: Insights from the CRIPTOFAST Trial
  • Low-Dose Rivaroxaban Fails to Halt Cognitive Decline in Low-Risk Atrial Fibrillation: Results from the BRAIN-AF Trial
  • Rethinking Hemodynamics in Aortic Stenosis: The Paradoxical Normal-Flow, Low-Ejection Fraction Phenotype and Post-TAVI Outcomes
  • TAVI vs. SAVR in Women: RHEIA Trial Reveals Distinctive Echocardiographic Advantages for Both Approaches
  • High Insulin Resistance Blunts the Superiority of Ticagrelor Over Clopidogrel in Minor Stroke Patients with CYP2C19 Mutations
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in